Alkem Laboratories Gets Germany GMP Certificate for Baddi Plant

Alkem Laboratories has received a Germany GMP certificate for its Baddi plant in India, marking another regulatory milestone for the pharmaceutical company’s global operations.

The certification was issued by the Department of Pharmacy (Human Medicines), Germany, confirming that the plant complies with Good Manufacturing Practice (GMP) standards required for pharmaceutical manufacturing.

The Germany GMP certificate will remain valid for three years from the date of inspection. According to an exchange filing dated 10 November 2025, the German health authority conducted an EU GMP inspection at the company’s Baddi unit between 4 November 2025 and 10 November 2025.

Also Read: Advancing Interventional Radiology in India Through Collaboration

The inspection concluded without any critical or major observations, the company said. A clean inspection outcome strengthens the company’s ability to supply medicines to regulated international markets, including Europe.

Alkem Laboratories operates across global pharmaceutical markets and focuses on the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company has continued expanding its manufacturing capabilities while maintaining compliance with international quality standards.

On the financial front, the company reported steady growth during the latest quarter. Consolidated net profit rose 2% year-on-year to Rs 653.53 crore in Q3 FY26, compared with Rs 640.79 crore recorded in Q3 FY25.

Revenue growth remained stronger, with net sales increasing 10.7% year-on-year to Rs 3,736.82 crore in the quarter ended 31 December 2025.

The latest Germany GMP certificate further strengthens Alkem Laboratories’ regulatory standing and supports its strategy to expand its presence in highly regulated global pharmaceutical markets.